A multiple-dose study of Gantenerumab(RO4909832) following subcutaneous injection in Japanese Alzheimer's Disease patients.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221807

Enrollment

Registered

2012-05-29

Start date

2012-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

investigational material(s) Generic name etc : Gantenerumab INN of investigational material : Gantenerumab Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Admi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria -Meet DSM-IV criteria for Dementia of the Alzheimer type -MMSE score : 16 to 26 etc.

Exclusion criteria

Exclusion criteria: -Meet the exclusion criteria of MRI at screening. -A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease. etc.

Design outcomes

Primary

Measure	Time frame
The safety, tolerability and pharmacokinetics Observation/examination	—

Secondary

Measure	Time frame
The preliminary pharmacodynamic effects Observation/examination	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026